Armin Winands and Jan Hellemans

Jul 03, 2018

Belgian genomics service provider Biogazelle has appointed Armin Winands as its new CEO. Winands most recently served as director of business development at ArcherDX. Over the past 23 years, he has also held senior sales positions at NuGEN Technologies, Ingenuity Systems, Ion Torrent Systems, Illumina, Affymetrix, and Molecular Dynamics. Winands replaces Jan Hellemans, who served as CEO of Biogazelle for the past 10 years and will now take on the role of chief technology officer.

More Like This

Nov 19, 2018

Jason Ryan

Jason Ryan will leave his post as CFO of Foundation Medicine to become chief operating and financial officer at Magenta Therapeutics, effective January 1 of 2019. Prior to joining Foundation Medicine, he held management positions for Taligen Therapeutics, Codon Devices, and Genomics Collaborative. Ryan holds a BS in economics from Bates College and an MBA from Babson College.

Nov 15, 2018

Roy Smythe

Roy Smythe has been appointed as CEO of SomaLogic. He will replace Alister Reynolds, who became CEO in early 2017 and who will remain on the company's board. Smythe joins the Boulder, Colorado-based firm from Royal Philips, where he was chief medical officer for strategy and partnerships. Prior to that, he was CMO at Valence Health, and before that, CMO of healthcare technology accelerator AVIA. Previously, he was chair of the Department of Surgery at Baylor Scott & White Health and the Texas A&M Health Science Center College of Medicine, where he was also medical director of innovation.

Nov 14, 2018

Glenn Miles

Cancer Genetics has appointed Glenn Miles as its chief financial officer, effective November 26, 2018. In addition, the company said that Igor Gitelman, its current chief accounting officer, will be departing.

Miles has more than 30 years' experience in a variety of accounting and finance roles and has been a full time contractor with Cancer Genetics since this July. Prior to joining Cancer Genetics, he served as President and CFO of management advisory firm Catalytic Consulting, was biopharma controller for Europe, Latin America and US oncology at Pfizer, and held various senior-level finance positions at Lehman Brothers and AT&T Mobility. He holds an MBA from Mercer University and bachelors in commerce and accounting from the University of Alabama.

Nov 13, 2018

Steve Ziganti, Patrik Jeanmonod, Jack Ball, Allen Poirson

Cytek Biosciences announced Steve Ziganti has joined the firm as vice president of worlwide sales and Patrik Jeanmonod has been hired as the company's chief financial officer. 

Additionally, Jack Ball and Allen Poirson have joined Cytek's board of directors. 

Ziganti was previously VP of sales and service at BD Biosciences before retiring from that firm. Jeanmonod has previously held executive positions in finance at Covance, Bridge Pharmaceuticals, and Synteract. He is currently a board member at Seal Biosciences. 

Ball formerly was the CEO of Amnis and CCO of Accuri Cytomers and Molecular Probes. Poirson is a partner at Mighty Capital and previously was CEO of Sony Biotechnology.

Nov 09, 2018

Anne Jones

Anne Jones has been appointed as CEO of Genomics Medicine Ireland. She joins the company from Danaher, where she was vice president and general manager for the Pall Corporations Lab, Food, and Beverage business. Prior to that, she was vice president of strategy and business development at Agilent Technologies. She also held various marketing and R&D roles at Amersham Biosciences in the UK and at GE Healthcare Life Sciences in the UK and the US. Jones holds a undergraduate degree in microbiology and molecular biology from the National University of Ireland and a PhD from Cancer Research UK.

Nov 08, 2018

Jeffrey Jeddeloh, Stephen Macevicz, Christine Peponnet

Jeffrey Jeddeloh, Stephen Macevicz, and Christine Peponnet have joined the new US subsidiary of French DNA synthesis firm DNA Script.  

Jeddeloh was appointed as vice president of business development and commercial strategy. Most recently, he was director of business development for Roche Molecular Solutions. Prior to that, he was R&D director at Orion Genomics. He holds a PhD from Washington University and an MBA from the University of Wisconsin.

Macevicz has become the firm's vice president of intellectual property. Previously, he was vice president of IP at Sequenta and at Ion Torrent, as well as senior IP attorney at Becton Dickinson. He holds a PhD in biophysics and a JD from the University of California, Berkeley.

Peponnet has joined the company as vice president of technology development. Most recently, she was head of the biosystems group at CEA (Center for Atomic Energy), where she helped to develop a microfluidic technology that was licensed to Advanced Liquid Logic, which was later acquired by Illumina. Prior to that, she worked at Caliper Technologies, and before that, she was head of genotyping R&D at Genset.

Nov 08, 2018

Jim Mullen

Jim Mullen has been elected to the board of directors of Thermo Fisher Scientific, bringing the total number of board members to 12. Previously, he was the CEO of Patheon, which Thermo Fisher acquired last year. Prior to that, he was the president and CEO of Biogen Idec. Mullen holds a bachelor of science degree in chemical engineering from Rensselaer Polytechnic Institute and a master's degree in business from Villanova University.

Nov 08, 2018

Scott Tomlins

Strata Oncology has appointed Scott Tomlins as the firm's chief medical officer. Prior to Strata, Tomlins was an associate professor of pathology at the University of Michigan. Tomlins will maintain an adjunct faculty position at the university's medical school. Tomlins' academic research has focused on applying high-throughput techniques to characterize the cancer genome and transcriptome to understand cancer biology and identify clinically relevant biomarkers and therapeutic targets. 

Nov 07, 2018

Scott Nicholson, Cory Dunn

Biocept has appointed Scott Nicholson as its Vice President of Sales in the US and Cory Dunn as its Vice President of Marketing. Nicholson has 24 years of experience in the medical laboratory industry with a focus in oncology for the physician and hospital markets. He has served as a sales manager, executive, district manager, and regional manager in prior positions. Most recently, Nicholson was vice president of sales at GenomeDx, where he led the commercialization effort for the firm's Decipher tests.

Dunn has over 15 years of commercial marketing experience, specializing in diagnostic testing services for oncology. She most recently served as VP of commercial marketing at GenomeDx, where she led the launch, commercial marketing, and product life cycle management of the Decipher suit of tests. Prior to GenomeDx, Dunn oversaw the marketing efforts for Plus Diagnostics' Gastroenterology, Dermatology and Hematology-Oncology product lines. She holds post graduate science and education degrees from the University of California, San Diego and Stanford University, respectively.

In connection with the hirings, Biocept said it granted each individual an inducement stock option award to purchase 24,200 shares of Biocept common stock, with an exercise price per share equal to the closing price of Biocept's common stock on October 31, 2018.

Nov 06, 2018

Marc Stapley

Marc Stapley plans to leave Illumina, effective Jan 1., 2019. Stapley is currently executive vice president of strategy and corporate development at Illumina, where he is responsible for corporate strategy, corporate and business development, and infrastructure. He joined Illumina in 2012 and has held multiple roles with the firm, including as chief financial officer and chief administrative officer. Prior to joining Illumina, he was senior vice president of finance at Pfizer.

Nov 05, 2018

Oved Amitay

Centogene has appointed Oved Amitay its chief business officer. He has almost 30 years of commercial and development experience with a focus on orphan drugs for patients with rare genetic diseases. Amitay joins Centogene from Arrett Neuroscience where he was president and COO. Prior to that he was VP, head of commercial at Alnylam Pharmaceuticals. 

Nov 02, 2018

Peter Collins

Peter Collins has stepped down as chief business officer and director of Premaitha Health, effective November 1. Previously, he was vice president and head of diagnostics at GlaxoSmithKline.

Nov 01, 2018

Susan Rolih

Meridian Bioscience said this week that Susan Rolih, executive VP of global regulatory and quality systems, will retire on Nov. 30, 2018. She worked for the firm for 18 years and is expected to serve as a consultant on an as-requested basis with matters related to FDA remediation efforts at the firm's Magellan Diagnostics business, among other matters.

Nov 01, 2018

Jan Groen

Liquid biopsy firm Angle has appointed Jan Groen as a non-executive director, effective Nov. 1. He is currently president and CEO of MDxHealth. Prior to joining that firm, he was president of US operations and global chief operating officer at Agendia. Groen is also a non-executive board member of SPL Medical. 

Nov 01, 2018

Jason Gammack

Gene editing technology company Inscripta has appointed Jason Gammack as its first chief commercial officer. Gammack will design and oversee Inscripta's sales, marketing, business development, and customer support operations. He most recently served as vice president of Qiagen's life science business, where he led the development of the life science portfolio and go-to-market strategy. Prior to Qiagen, Gammack developed commercialization growth strategies at bioinformatics company Ingenuity Systems, which was acquired by Qiagen in 2013, and has also held senior leadership roles at Sigma-Aldrich, Life Technologies, Affymetrix, and Promega.  

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.